Brazil

Population 2018  209 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>95 (81–110)</td>
<td>45 (39–52)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>11 (9.3–13)</td>
<td>5.2 (4.4–6)</td>
</tr>
<tr>
<td>MDR-R/RR-TB incidence</td>
<td>2.5 (1.9–3.2)</td>
<td>1.2 (0.89–1.5)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.8 (4.6–5)</td>
<td>2.3 (2.2–2.4)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>1.9 (1.4–2.4)</td>
<td>0.88 (0.68–1.1)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis 34%
- % with known HIV status 79%
- % pulmonary 87%
- % bacteriologically confirmed*** 74%
- % children aged 0-14 years 3%
- % women 29%
- % men 68%
Total cases notified 90 527

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018 87% (75–100)
TB patients facing catastrophic total costs TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (6–8)

TB/HIV care in new and relapse TB patients, 2018
- Patients with known HIV status who are HIV-positive 7 445 11%
  - on antiretroviral therapy 3 776 51%

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance *** 43%
  - New cases 43%
  - Previously treated cases 48%
Laboratory-confirmed cases* MDR/RR-TB: 1 119, XDR-TB: 26
Patients started on treatment* ** MDR/RR-TB: 746, XDR-TB: 26
MDR/RR-TB cases tested for resistance to second-line drugs 141

Treatment success rate and cohort size
New and relapse cases registered in 2017 71% 78 652
Previously treated cases, excluding relapse, registered in 2017 39% 7 350
HIV-positive TB cases registered in 2017 51% 7 617
MDR-R/RR-TB cases started on second-line treatment in 2016 61% 546
XDR-TB cases started on second-line treatment in 2016 41% 17

TB preventive treatment, 2018
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019
National TB budget (US$ millions) 38
Funding source: 100% domestic, <1% international, 0% unfunded

Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-05